SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-037624
Filing Date
2024-03-28
Accepted
2024-03-28 07:45:12
Documents
15
Period of Report
2024-03-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20240328.htm   iXBRL 8-K 45165
2 EX-99.1 cadl-ex99_1.htm EX-99.1 46928
3 GRAPHIC img160460863_0.jpg GRAPHIC 21194
4 GRAPHIC img160460863_1.jpg GRAPHIC 76059
5 GRAPHIC img160460863_2.jpg GRAPHIC 28088
  Complete submission text file 0000950170-24-037624.txt   392218

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20240328.xsd EX-101.SCH 27879
18 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20240328_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 24793555
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)